Asia-Pacific Pharmacists Unveil First-Ever Peripheral Neuropathy Management Guidelines
In a landmark development for regional healthcare, leading pharmacist experts from across the Asia-Pacific region, in partnership with P&G Health, have announced the creation of the area's first comprehensive guidelines specifically designed for community pharmacists. These guidelines provide a structured framework to identify, assess, and manage patients suffering from peripheral neuropathy (PN) within everyday pharmacy practice.
Addressing a Widespread and Underdiagnosed Condition
The newly released "Empowering Community Pharmacists - Expert Consensus Guidelines for the Effective Management of Peripheral Neuropathy with Neurotropic B Vitamins" aims to translate complex clinical evidence into practical, culturally adaptable recommendations. The primary goal is to standardize pharmacy-based screening, patient counseling, and stepwise management protocols, thereby narrowing the persistent and dangerous gap of underdiagnosis and delayed treatment that plagues the region.
Dr. Yolanda R. Robles, Lead Author and Chairperson, Professor at the University of the Philippines College of Pharmacy and President of the Federation of Asian Pharmaceutical Associations (FAPA), emphasized the critical need for this initiative. "Peripheral neuropathy is a widespread and often debilitating condition with a high prevalence among diabetic patients in APAC," she stated, citing prevalence rates from 21% in Australia to 58% in the Philippines and Indonesia. "With pharmacists being the most accessible health professionals in many APAC countries, this consensus translates the best available evidence into simple, actionable steps. This empowers pharmacists to spot PN earlier, guide patients more confidently, and partner effectively with physicians to improve long-term health outcomes."
Transforming Pharmacists into Proactive Care Partners
The guidelines represent a significant shift in the role of community pharmacists, moving them from a reactive model focused on dispensing medication to a proactive one centered on early detection and timely intervention. According to Dr. Apt. Lusy Noviani of the Indonesian Pharmacist Association (IAI), this evolution is crucial. "From behind the counter to the frontline, APAC pharmacists are now positioned for early detection and proactive care," she explained. "In countries like Indonesia, where doctor-to-population ratios are low, community pharmacists play an absolutely critical role in early screening and reducing dangerous delays in PN care."
To facilitate this new role, the guidelines equip pharmacists with specific, practical tools. These include applying a newly created risk-assessment mnemonic called MEDIC (M – Medication, E – Elderly, D – Diabetes, I – Infection, C – Chronic), differentiating nerve pain from muscle pain, utilizing validated in-pharmacy screening questionnaires, initiating appropriate counseling, considering suitable over-the-counter options including therapeutic-dose neurotropic B vitamins (B1, B6, B12), and ensuring prompt referral when red flags are present.
Dr. Navin Kumar Loganadan, a Contributing Author from Malaysia, highlighted the simplicity of the MEDIC tool. "In busy pharmacy settings, simple tools matter. MEDIC is an easy-to-remember risk mnemonic that allows pharmacists to flag patients at high risk of nerve damage early—without diagnosing—and effectively guide the next steps in care."
A Clear Pathway from Screening to Support
The consensus provides a clear, structured care pathway designed for real-world pharmacy environments. Dr. Kenny James P. Merin from Lyceum of the Philippines University – Davao noted, "This guideline is about practical, everyday pharmacy. The steps are clear: identify risk, screen, counsel, consider therapeutic-dose B1, B6, and B12 where appropriate, and follow up consistently. With structured algorithms and checklists, pharmacists can standardize high-quality care without disrupting their workflow."
The guidelines also address a common issue: patient self-medication with inappropriate doses of vitamin B products, which can lead to inefficacy or even worsen symptoms. Dr. Kitiyot Yotsombut from Chulalongkorn University in Thailand added, "Therapeutic-dose neurotropic B vitamins have a role in comprehensive PN management for suitable patients, but it requires the right dose and duration. Our guideline emphasizes pharmacist vigilance—reassessing at 3–6 months, watching for red flags, and collaborating closely with physicians."
Implementation and Access Through P&G Nerve Connect
To ensure widespread adoption, the expert consensus guideline will be made available to APAC pharmacists via a newly launched digital resource portal called P&G Nerve Connect, alongside expert-led webinars across key countries including the Philippines, Indonesia, Malaysia, Thailand, and Singapore.
Shraddha Vohra, Vice President of Personal Health Care Asia Pacific at P&G Health Singapore, described the portal as a "one-stop center for nerve health," bringing together real-world patient case insights and practical tools. "Pharmacists who face high patient flow and multiple tasks will have access to essential resources like checklists and training videos. They will also be encouraged to submit their own patient cases to inspire their community and exchange learnings across APAC," she shared.
Dr. Robles underscored the importance of ongoing education, referencing a recent pharmacist survey in the Philippines. "Behavior change is never easy. Our survey showed that pharmacists completing five or more training sessions demonstrated significantly better knowledge on the right dose of B vitamins for PN. P&G Health’s Nerve Connect provides an always-on omnichannel education solution, transforming paper-based guidelines into engaging, everyday pharmacist practices."
The guideline is explicitly unbranded and intended strictly for healthcare professional use. It is designed to complement, not replace, physician diagnosis and care. All pharmacists are advised to adhere strictly to local regulations governing their scope of practice, screening procedures, and referral protocols.
